SecBot SecBot

GLMD

Galmed Pharmaceuticals Ltd.
Nasdaq· Pharmaceutical Preparations· Inc. L3· CIK 0001595353 Biotech & Drug Discovery
Former ticker of Galmed Pharmaceuticals Ltd. · EOCN stock page →
—
Market cap
$4.8M
Nano cap
Since first trade
−5.2%
from $3.82 · Sep 14
30 days
−0.3%
from $3.63
Range since listing
$3.36–3.82
−5% from high · low Oct 6
Avg volume 13D
7.6K
shares / day
Short interest
19.6K
≈1.9% of shares · −47.3%
Days to cover
1.0
at average volume
Filing reports
15
analyzed by SecBot
SecBot read MIXED 6 reports · 90 days
Balance 1 bearish · 1 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 2/6
Strongest BEARISH Galmed Pharmaceuticals' shelf registration (File No. 333-289703) was declared effective by the SEC on…
All reports →

Price

Daily candles with volume.

Signal stack

Where each data set points today.

  • EstimatesFLAT

    Current-quarter EPS estimate −$3.120 → −$3.060 over 90 days.

  • Short sellersCOVERING

    Short interest −47.3% to 19.6K shares. 1.0 days to cover, ≈1.9% of shares.

The Street

last action Apr 2025
Recent actions
DateFirmActionRating
Apr 4, 2025Maxim Group
DOWNGRADE
DOWNGRADEHold
Jul 24, 2023Maxim Group
UPGRADE
UPGRADEBuy
Aug 8, 2022Maxim Group
DOWNGRADE
DOWNGRADEHold
Aug 8, 2022Canaccord Genuity
DOWNGRADE
DOWNGRADEHold
May 18, 2022Raymond James
DOWNGRADE
DOWNGRADEMarket Perform
May 3, 2022HC Wainwright & Co.
DOWNGRADE
DOWNGRADENeutral

Earnings setup

Estimates
−$3.06
EPS estimate, this quarter
+2%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$3.06-$3.06–-$3.06+1.9%$0.00
Next Q-$3.17-$3.17–-$3.17+0.9%$0.00
Current FY-$11.41-$11.41–-$11.41+8.6%$0.00
Next FY-$2.17-$2.17–-$2.17+69.9%$190.0K
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 10, 2026
Listing
Delisted: GLMD — removed from the Nasdaq symbol directory
Galmed Pharmaceuticals Ltd. - Ordinary Shares
Sep 3, 2026
Listing
Listing Status: GLMD — Normal (was Deficient)
Galmed Pharmaceuticals Ltd. - Ordinary Shares | Nasdaq Financial Status Indicator D → N
Aug 26, 2026
Earnings date
GLMD Q2 2026 Earnings Scheduled — 2026-08-26
Aug 19, 2026
Trading halt
Halt Resumed: GLMD — trading resumed after T3 (News and Resumption Times)
Halted 2026-08-18T23:50:00.000Z | Resumed 2026-08-19T13:00:00.000Z
Aug 18, 2026
Trading halt
Trading Halt: GLMD — T1 (News Pending)
Galmed Pharmaceuticals Ltd | Market: NASDAQ | Code: T1 — News Pending

Short side

FINRA· Aug 31, 2026
19,643
shares short
-47.3%
vs prior settlement
1.0
days to cover
≈1.9%
of shares outstanding
Trading halts
Aug 18, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 10, 2026 Listing status
Delisted: GLMD — removed from the Nasdaq symbol directory
Galmed Pharmaceuticals Ltd. - Ordinary Shares
Sep 9, 2026 SEC
Galmed Pharmaceuticals rebranded to Eocene Ltd., changing its Nasdaq ticker to EOCN effective September 10, 2026, and…
6-K — Impact 4/10
Sep 4, 2026 SEC
Galmed Pharmaceuticals' shelf registration (File No. 333-289703) was declared effective by the SEC on September 3…
EFFECT — Impact 5/10
Sep 3, 2026 SEC
Galmed Pharmaceuticals held its Annual General Meeting on September 3, 2026, and all proposals were approved by…
6-K — Impact 2/10

SecBot reports

15 filings · 7 bullish · 1 bearish · 7 neutral
All GLMD filing & press-release reports (15)